KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$6.57 USD
0.00 (0.00%)
Updated Jun 7, 2024 02:58 PM ET
After-Market: $6.22 -0.35 (-5.33%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth D Momentum F VGM
Brokerage Reports
KALA BIO, Inc. [KALA]
Reports for Purchase
Showing records 101 - 120 ( 365 total )
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS- & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
EYSUVIS Commercial Coverage Expands Beyond 88 Million Lives
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Financial Results Reported; Reiterate Buy; Lowering PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Q1: EYSUVIS Momentum Building as INVELTYS Wades Through the Pandemic
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L